Back كونفيديسيا Arabic Convidecia Catalan Convidecia Czech Convidecia Spanish کان‌سینو Persian Ad5-nCoV French Convidecia ID Convidecia Italian Ad5-nCoV Japanese 칸시노 코로나19 백신 Korean

Convidecia

AD5-nCOV
A multi-dose vial of Convidecia (AD5-nCOV) filled and finished in Mexico
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Trade namesConvidecia
Other namesPakVac
Routes of
administration		Intramuscular, Nebulizer
ATC code
Legal status
Legal status
Identifiers
DrugBank
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
2024
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Society
virus icon COVID-19 portal

AD5-nCOV, trade-named Convidecia, is a single-dose[1] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina,[2] Chile,[3] Mexico,[4] Pakistan,[5] Russia,[6] and Saudi Arabia[7] with 40,000 participants.

In February 2021, global data from Phase III trials and 101 COVID cases showed that the intramuscular version of the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[8] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[9][1] Convidecia is similar to other viral vector vaccines like AZD1222, Gam-COVID-Vac, and Ad26.COV2.S.[10] Its single-dose regimen and normal refrigerator storage requirement (2° to 8 °C) could make it a favorable vaccine option for many countries.[9] It is currently under evaluation for emergency use listing by the WHO.[11] On May 19 2022, WHO issued EUL for the vaccine.[12]

A Phase I study published in The Lancet showed two doses of a nebulised version of Convidecia (inhaled through the mouth) resulted in neutralising antibody responses similar to the existing one-dose injection.[13]

Convidecia and the Pakistani version called PakVac are approved for use by some countries in Asia,[14][15][16] Europe,[17][18] and Latin America.[19][20][21] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[22] with filling and finishing of the vaccine additionally also taking place in Malaysia,[16] Mexico,[23] and Pakistan.[24]

  1. ^ a b "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that has 65% efficacy". Fortune. Retrieved 2021-02-11.
  2. ^ Cite error: The named reference :0 was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference :9 was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference :10 was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference NCT04526990 was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference :11 was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference :12 was invoked but never defined (see the help page).
  8. ^ "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Retrieved 2021-02-08.
  9. ^ a b "China's CanSino Covid Vaccine Shows 65.7% Efficacy". Bloomberg.com. 2021-02-08. Retrieved 2021-02-10.
  10. ^ Zimmer C, Corum J, Wee SL (2020-06-10). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2020-12-12.
  11. ^ "Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process" (PDF). World Health Organization. 15 July 2021. Archived (PDF) from the original on 2021-07-16.
  12. ^ "WHO Validates 11th Vaccine for COVID-19". World Health Organization. 19 May 2022.
  13. ^ Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, et al. (July 2021). "Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial". The Lancet. Infectious Diseases. 21 (12): 1654–1664. doi:10.1016/S1473-3099(21)00396-0. PMC 8313090. PMID 34324836.
  14. ^ Cite error: The named reference :13 was invoked but never defined (see the help page).
  15. ^ Cite error: The named reference arynews.tv was invoked but never defined (see the help page).
  16. ^ a b Cite error: The named reference :3 was invoked but never defined (see the help page).
  17. ^ Cite error: The named reference Ashok was invoked but never defined (see the help page).
  18. ^ "Membrii NITAG au venit cu recomandări privind utilizarea vaccinurilor împotriva COVID-19 în Republica Moldova". Ministerul Sănătății, Muncii și Protecţiei Sociale. 2021-03-03. Retrieved 2021-05-21.
  19. ^ Cite error: The named reference :17 was invoked but never defined (see the help page).
  20. ^ "Argentina issues emergency approval to China's single-dose Cansino COVID-19 vaccine". Reuters. 2021-06-11. Retrieved 2021-06-11.
  21. ^ "ISP Approves Emergency Use And Importation Of Cansino Vaccine To Fight COVID-19". Institute of Public Health of Chile. Archived from the original on 2021-04-07. Retrieved 2021-04-08.
  22. ^ "China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year". finance.yahoo.com. 27 February 2021. Archived from the original on 2021-02-27. Retrieved 2021-02-28.
  23. ^ Cite error: The named reference :6 was invoked but never defined (see the help page).
  24. ^ "Pakistan develops homemade anti-Covid vaccine 'PakVac'". The Express Tribune. 2021-05-24. Retrieved 2021-05-25.

Rich TVX News Network Site

Rich TVX News Network Info

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search